Samaritan Pharmaceuticals, Inc.

Research and development of novel therapeutic and diagnostic products to treat AIDS, Alzheimer’s, central nervous system disorders, cancer, and cardiovascular diseases.

Samaritan Pharmaceuticals, Inc. was formed in September 1994 and became public in October 1997. The company collaborates with Georgetown University. Since August 2004 Samaritan Pharmaceuticals is listed on the American Stock Exchange under the ticker symbol LIV (AMEX).

Janet Greeson, Dr., CEO, President, Director
Eugene Boyle, CFO
Thomas Lang, PhD, Chief Drug Development Officer

Janet Greeson
Eugene Boyle
Laurent Lecanu, Dr.
Erasto R.C. Saldi, MD
H. Thomas Winn
Cynthia Thompson
Budd Holden
Julio Garcia,Dr., M.D.,

Erasto R. C. Saldi, MD, Chairman
Laurent Lecanu, Dr.
Jean-Paul Tillement, Dr.
Julio Garcia, Dr., MD
Ewa K. Carrier, Dr., MD
Pauline Nys, Dr.
Vassilios Papadopoulos, Dr.
Brian Salzman, Dr., MD

101 Convention Center Drive, Suite 310
Las Vegas, Nevada 89109
USA
Phone: +1-702-735-7001
Fax: +1-702-737-7016

To date Samaritan has in-licensed twelve innovations from Georgetown University, Washington. Samaritan Pharmaceuticals’ products are built upon a cholesterol-metabolism and glucocorticoid-biosynthesis technology platform.

The regulation of endogenous steroid synthesis is thought to be a successful therapeutic approach to treat various steroid-dependent pathologies such as Alzheimer’s, anxiety disorders, cancer, depression, high cholesterol and HIV. SP-01A and SP-10 are oral antiviral adjuvants indicated in the treatment of HIV-infected individuals. The molecules prevent the entry of the HIV virus into target cells and protects them. Thus the virus does not develop resistance to SP-01A and SP-10.

Drug candidates for the treatment of Alzheimer’s disease are designed to modulate serum cortisol levels, because there seems to be a connection between high cortisol levels and hypertension, depression, memory loss and Alzheimer’s disease. The company’s Alzheimer animal (rat) model is a scientific tool for testing new Alzheimer’s drugs.

Samaritan is also developing a diagnostic blood test for breast cancer. The blood test measures whether a tumour is aggressive in nature as well as the likelihood of a cancerous tumour to metastasise. The test detects high levels of the protein peripheral-type benzodiazepine receptor (PBR). SP-1000 is a peptide for lowering LDL cholesterol levels in order to prevent cardiovascular deseases.

Samaritan Pharmaceuticals has completed the Phase II trial of SP-01.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.